Danaher Q2 revenue, adjusted EPS beats on life sciences segment strength; raises outlook

Overview

• US life sciences and diagnostics firm's Q2 revenue rose, beating analyst expectations

• Adjusted EPS for Q2 grew 8% and beat analyst expectations

• Company raised full-year adjusted EPS guidance after strong Q2 and Masimo acquisition

Outlook

• Danaher expects Q3 2026 non-GAAP core revenue growth of 2.0% to 3.0% year-over-year

• Company raises full-year 2026 adjusted diluted EPS guidance to $8.45-$8.60

• Danaher expects full-year 2026 non-GAAP core revenue growth of 3.0% to 4.0% year-over-year

Result Drivers

• LIFE SCIENCES STRENGTH - Life Sciences segment delivered its strongest quarter in several years, per CEO Rainer M. Blair

• BIOPROCESSING ORDERS - Bioprocessing revenue was impacted by customer project timing, but orders grew mid-teens and underlying trends remained strong, per CEO

• MASIMO ACQUISITION - Earlier-than-anticipated completion of Masimo acquisition enabled increased full-year adjusted EPS guidance

Company press release: ID:nPnb1mTsZa

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment technology peer group is "buy"

• Wall Street's median 12-month price target for Danaher Corp is $237.50, about 18.1% above its July 20 closing price of $201.11

• The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 22 three months ago

Reuters Recommended Reads

• July 20 - Tempus to acquire Personalis for $1.5 billion

• July 21 - Switzerland's Novartis beats Q2 sales estimates on strong sales across priority brands

• July 20 - Cardinal Health to buy AdaptHealth diabetes unit, Strive Medical for $360 million

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)